Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Adia Nutrition Inc. (OTC Pink: ADIA) has filed for uplisting to the OTCQB Venture Market following a successful independent audit with Astra Audit and Advisory on April 1, 2025. The company specializes in regenerative medicine and nutritional wellness, focusing on stem cell therapies and nutritional products.
As part of the uplisting process, OTC Markets will handle Adia's Form 15c2-11, streamlining the broker-dealer quotation process and enhancing transparency. The company has also requested the Non-Objecting Beneficial Owners (NOBO) list to improve direct shareholder communication.
CEO Larry Powalisz emphasized that these strategic moves align with the company's commitment to transparency and growth. The uplisting is part of Adia's broader roadmap toward a potential Nasdaq Small Cap listing, aiming to enhance market credibility and expand its investor base while continuing to develop its clinic network and regenerative medicine solutions.
Adia Nutrition Inc. (OTC Pink: ADIA) ha presentato richiesta per il passaggio al OTCQB Venture Market dopo un audit indipendente di successo con Astra Audit and Advisory il 1 aprile 2025. L'azienda si specializza in medicina rigenerativa e benessere nutrizionale, concentrandosi su terapie con cellule staminali e prodotti nutrizionali.
Come parte del processo di uplisting, OTC Markets gestirà il modulo 15c2-11 di Adia, semplificando il processo di quotazione per i broker-dealer e migliorando la trasparenza. L'azienda ha anche richiesto l'elenco dei Beneficiari Non Obiettori (NOBO) per migliorare la comunicazione diretta con gli azionisti.
Il CEO Larry Powalisz ha sottolineato che queste mosse strategiche sono in linea con l'impegno dell'azienda verso la trasparenza e la crescita. L'up-listing fa parte di una roadmap più ampia di Adia verso una potenziale quotazione nel Nasdaq Small Cap, con l'obiettivo di migliorare la credibilità di mercato e ampliare la sua base di investitori, continuando a sviluppare la propria rete clinica e le soluzioni di medicina rigenerativa.
Adia Nutrition Inc. (OTC Pink: ADIA) ha presentado una solicitud para el ascenso al OTCQB Venture Market tras una auditoría independiente exitosa con Astra Audit and Advisory el 1 de abril de 2025. La empresa se especializa en medicina regenerativa y bienestar nutricional, centrándose en terapias con células madre y productos nutricionales.
Como parte del proceso de ascenso, OTC Markets manejará el formulario 15c2-11 de Adia, agilizando el proceso de cotización para los corredores de bolsa y mejorando la transparencia. La empresa también ha solicitado la lista de Propietarios Beneficiarios No Objetores (NOBO) para mejorar la comunicación directa con los accionistas.
El CEO Larry Powalisz enfatizó que estos movimientos estratégicos están alineados con el compromiso de la empresa con la transparencia y el crecimiento. El ascenso es parte de una hoja de ruta más amplia de Adia hacia una posible cotización en el Nasdaq Small Cap, con el objetivo de mejorar la credibilidad del mercado y expandir su base de inversores, mientras continúa desarrollando su red clínica y soluciones de medicina regenerativa.
Adia Nutrition Inc. (OTC Pink: ADIA)는 2025년 4월 1일 Astra Audit and Advisory와의 성공적인 독립 감사 후 OTCQB Venture Market로의 상장을 신청했습니다. 이 회사는 줄기 세포 치료 및 영양 제품에 중점을 두고 재생 의학 및 영양 웰빙을 전문으로 합니다.
상장 과정의 일환으로 OTC Markets는 Adia의 15c2-11 양식을 처리하여 중개인 및 딜러의 인용 과정을 간소화하고 투명성을 향상시킬 것입니다. 회사는 또한 직접 주주 소통을 개선하기 위해 비대상 유익 소유자(NOBO) 목록을 요청했습니다.
CEO Larry Powalisz는 이러한 전략적 조치가 회사의 투명성과 성장에 대한 헌신과 일치한다고 강조했습니다. 상장은 Adia의 더 넓은 로드맵의 일환으로, 잠재적인 Nasdaq Small Cap 상장을 목표로 시장 신뢰성을 높이고 투자자 기반을 확장하며 클리닉 네트워크와 재생 의학 솔루션을 계속 개발하는 것입니다.
Adia Nutrition Inc. (OTC Pink: ADIA) a déposé une demande de passage au OTCQB Venture Market suite à un audit indépendant réussi avec Astra Audit and Advisory le 1er avril 2025. L'entreprise se spécialise dans la médecine régénérative et le bien-être nutritionnel, en se concentrant sur les thérapies par cellules souches et les produits nutritionnels.
Dans le cadre du processus de passage, OTC Markets s'occupera du formulaire 15c2-11 d'Adia, simplifiant le processus de cotation pour les courtiers et améliorant la transparence. L'entreprise a également demandé la liste des Propriétaires Bénéficiaires Non Objectionnels (NOBO) pour améliorer la communication directe avec les actionnaires.
Le PDG Larry Powalisz a souligné que ces mouvements stratégiques s'alignent avec l'engagement de l'entreprise envers la transparence et la croissance. Le passage fait partie d'une feuille de route plus large d'Adia en vue d'une éventuelle cotation sur le Nasdaq Small Cap, visant à renforcer la crédibilité du marché et à élargir sa base d'investisseurs tout en continuant à développer son réseau clinique et ses solutions de médecine régénérative.
Adia Nutrition Inc. (OTC Pink: ADIA) hat einen Antrag auf Auflistung im OTCQB Venture Market gestellt, nachdem am 1. April 2025 eine erfolgreiche unabhängige Prüfung durch Astra Audit and Advisory durchgeführt wurde. Das Unternehmen ist auf regenerative Medizin und Ernährungswohlbefinden spezialisiert und konzentriert sich auf Stammzelltherapien und Ernährungsprodukte.
Im Rahmen des Auflistungsprozesses wird OTC Markets das Formular 15c2-11 von Adia bearbeiten, um den Quotierungsprozess für Broker-Dealer zu optimieren und die Transparenz zu erhöhen. Das Unternehmen hat außerdem die Liste der Nicht-Widersprechenden Begünstigten (NOBO) angefordert, um die direkte Kommunikation mit den Aktionären zu verbessern.
CEO Larry Powalisz betonte, dass diese strategischen Schritte mit dem Engagement des Unternehmens für Transparenz und Wachstum übereinstimmen. Die Auflistung ist Teil eines umfassenderen Fahrplans von Adia, um eine potenzielle Nasdaq Small Cap-Notierung anzustreben, die darauf abzielt, die Marktcredibilität zu erhöhen und die Investorenbasis zu erweitern, während weiterhin das Kliniknetzwerk und die Lösungen der regenerativen Medizin entwickelt werden.
- Filing for OTCQB uplisting indicates market progression and enhanced visibility
- Successful completion of independent audit demonstrates financial compliance
- Streamlined 15c2-11 process through OTC Markets improves trading efficiency
- Strategic path toward potential Nasdaq Small Cap listing shows growth trajectory
- None.
Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products.
As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery-key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach.
Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work-such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)-while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities.
"We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence."
With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine.
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247981
FAQ
What is the significance of Adia Nutrition's (ADIA) OTCQB uplisting filing in April 2025?
How will OTC Markets handling ADIA's Form 15c2-11 benefit the company?
What is the purpose of ADIA requesting the NOBO list in 2025?
What are ADIA's long-term market objectives beyond the OTCQB uplisting?
